Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT04780958 |
Other study ID # |
TTU-2020-8630 |
Secondary ID |
|
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
June 1, 2020 |
Est. completion date |
January 31, 2021 |
Study information
Verified date |
March 2021 |
Source |
Ataturk University |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Retinol and retinol binding protein were studied in the umbilical cord blood of 44 preterm
infants with gestation age of < 30 weeks. Serum retinol and RBP levels were determined by
enzyme-linked immunosorbent assay. The rate of transplacental retinol passage was calculated.
The demographic data of mother and baby, vitamin use in the mother, antenatal steroid
application and diseases diagnosed during pregnancy were recorded. An evaluation was made of
the retinol, RBP and factors of the mother and baby affecting the transplacental retinol
passage. The relationship between retinol and retinol binding protein levels and neonatal
mortality and morbidity was investigated.
Description:
Study Population Babies born at this hospital with a gestational week of <30 were included in
the study. Patients were excluded in the presence of a major abnormality or known congenital
metabolic disease in the mother or baby, and the presence of chronic liver, kidney or
gastrointestinal system disease in the mother, or if the family did not give consent. A
record was made of the gender and birth weight of the babies and gestation week, maternal
age, gravidity, status of vitamin intake and use of vitamin A during pregnancy, and antenatal
steroid administration in the mothers. A record was made of the presence of early membrane
rupture (EMR) diagnosed during the present pregnancy of the mother, preeclampsia/eclampsia,
pregnancy-induced hypertension, urinary infection, gestational diabetes mellitus and anemia,
if present. We recorded also neonatal mortality and morbidity such as respiratory distress
syndrome, retinopathy of prematurity, necrotizing enterocolitis, intraventricular hemorrhage,
bronchopulmonary dysplasia,
Sampling and Test Study Method Umbilical cord blood was drawn at birth in all babies included
in the study by experienced individuals using a vacutainer. Approximately 6 ml of venous
blood was also drawn from the antecubital region of the mothers immediately after the birth
in a biochemistry tube, and centrifuged for 10 minutes at 4500 rpm after the completion of
coagulation, and the sera were separated. Serum samples were frozen and stored at -80° until
the analysis was performed. For the analysis, serum samples were thawed in appropriate
circumstances and all analyzes were performed at the Medical Biochemistry Laboratory of
Atatürk University at a single session.
In the serum samples, the retinol levels were analyzed using ELISA kits from the Bioassay
Technology Laboratory ( E1548 Hu Jiaxing, Zhejiang, China), RBP levels were analyzed using
ELISA kits of Elabscience (E-EL-H1581 Texas USA) following the standard protocol suggested by
the manufacturer at the Dynex automated ELISA reading device (Dynex Technologies
Headquarters, Chantilly, USA). The measurement range of the kit for retinol and RBP was
2ng/ml- 800 ng/ml and 0,07 - 100 ng/mL, respectively.
The formula "umbilical cord retinol/maternal retinol x100" was used for the calculation of
placental retinol passage rate in order to show the percentage of maternal retinol passing to
the umbilical cord .
Retinol deficiency was evaluated according to the WHO data. A level of < 20 µg/dl was
accepted as a deficiency. The level of deficiency was accepted as < 200 ng/ml since the unit
used in this present study was ng/ml.